Proteus vulgaris Response to Various Antibacterial Agents
Futuristic Biotechnology · 2021
DOI: 10.54393/fbt.v1i02.9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Futuristic Biotechnology, 2021. Verfasst von Ansar Abbas und 2 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Proteus vulgaris is commonly associated with urinary tract infections, wound infections and sepsis. The ability of microorganisms to resist antibiotic actions is referred to as antibiotic resistance.
Objective
To compare the antibacterial effects of various medications on clinical isolates of P. vulgaris was the goal.
Methods
Over the course of a year, 1000 samples were collected in a cross-sectional study at a hospital in Lahore, Pakistan. The Kirby-Bauer disc diffusion technique was used to test for antibiotic susceptibility.
Results
It was determined that the most efficient antibacterial medicines against P. vulgaris. were Imipenem, Gentamycin, Amikacin, Augmentin, Linezolid, Levofloxacin, Ceftazidime, Norfloxacine, and Cefazolin. On the other hand, Meropenem, Cephalothin, Rifampicin, Cefoxitin, and Ampicillin had little effect on Proteus vulgaris.
Conclusions
The study emphasizes the significance of preventative measures, such as responsible antibiotic use, the development of novel treatments, and the application of infection control techniques in healthcare settings, to effectively manage and prevent the spread of resistance. Antibiotic resistance in P. vulgaris is becoming a growing cause for concern.
Zitieren
APA
Abbas, A., Muzammil, H. S., & Asif, H. (2021). Proteus vulgaris Response to Various Antibacterial Agents. Futuristic Biotechnology. https://doi.org/10.54393/fbt.v1i02.9
Vancouver
Abbas A, Muzammil HS, Asif H. Proteus vulgaris Response to Various Antibacterial Agents. Futuristic Biotechnology. 2021. doi:10.54393/fbt.v1i02.9
BibTeX
@article{Abbas2021,
author = {Abbas, Ansar and Muzammil, Hafiz Shahzad and Asif, Hina},
title = {Proteus vulgaris Response to Various Antibacterial Agents},
journal = {Futuristic Biotechnology},
year = {2021},
doi = {10.54393/fbt.v1i02.9}
}
EUVIMED